Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

A phase II study from Indiana University

A. Kurup, C. W. Lin, D. J. Murry, L. Dobrolecki, D. Estes, Constantin Yiannoutsos, L. Mariano, C. Sidor, R. Hickey, Nasser Hanna

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalAnnals of Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Angiostatins
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
Angiogenesis Inhibitors
Pleural Effusion
Neutropenia
Dyspnea
Area Under Curve
Fatigue
Blood Vessels
Disease Progression
Adenocarcinoma
Maintenance
Hemorrhage
Neoplasm Metastasis
Survival
Brain

Keywords

  • Angiogenesis
  • Carboplatin
  • Lung cancer
  • Paclitaxel
  • RhAngiostatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer : A phase II study from Indiana University. / Kurup, A.; Lin, C. W.; Murry, D. J.; Dobrolecki, L.; Estes, D.; Yiannoutsos, Constantin; Mariano, L.; Sidor, C.; Hickey, R.; Hanna, Nasser.

In: Annals of Oncology, Vol. 17, No. 1, 01.2006, p. 97-103.

Research output: Contribution to journalArticle

@article{6fd48ebe1c494efe925589c755f04d06,
title = "Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University",
abstract = "Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-na{\"i}ve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54{\%} PS 1, 83.3{\%} stage IV and 62.5{\%} adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8{\%}, neutropenia 39.1{\%}, dyspnea 39.1{\%}, vascular 26.1{\%} and infection 17.4{\%}. The overall response rate was 39.1{\%}, 39.1{\%} stable disease and 21.7{\%} progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8{\%}. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.",
keywords = "Angiogenesis, Carboplatin, Lung cancer, Paclitaxel, RhAngiostatin",
author = "A. Kurup and Lin, {C. W.} and Murry, {D. J.} and L. Dobrolecki and D. Estes and Constantin Yiannoutsos and L. Mariano and C. Sidor and R. Hickey and Nasser Hanna",
year = "2006",
month = "1",
doi = "10.1093/annonc/mdj055",
language = "English",
volume = "17",
pages = "97--103",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

T2 - A phase II study from Indiana University

AU - Kurup, A.

AU - Lin, C. W.

AU - Murry, D. J.

AU - Dobrolecki, L.

AU - Estes, D.

AU - Yiannoutsos, Constantin

AU - Mariano, L.

AU - Sidor, C.

AU - Hickey, R.

AU - Hanna, Nasser

PY - 2006/1

Y1 - 2006/1

N2 - Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

AB - Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

KW - Angiogenesis

KW - Carboplatin

KW - Lung cancer

KW - Paclitaxel

KW - RhAngiostatin

UR - http://www.scopus.com/inward/record.url?scp=29844452745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844452745&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj055

DO - 10.1093/annonc/mdj055

M3 - Article

VL - 17

SP - 97

EP - 103

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -